An FDA advisory panel offered some key though largely lukewarm support for Eli Lilly’s experimental lung cancer drug necitumumab. While there was no formal vote for or against approval, committee members weighed the positives and negatives of a drug that showed only a marginal survival advantage for patients–but a big enough plus for patients that has warranted approvals in the past. And on balance, most supported an approval for Lilly during a roundtable discussion.

…read more

Source: UPDATED: Eli Lilly gains FDA advisers’ support for a questionable lung cancer drug


0 No comments